Inhibikase Therapeutics, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Inhibikase Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2022-03-31 was $67.00K, a 10.94% increase year-over-year.
- Inhibikase Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2021-03-31 was $60.39K, a 1139.81% increase year-over-year.
- Inhibikase Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2020-03-31 was $4.87K.
- Inhibikase Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2022 was $67.00K, a 10.94% increase from fiscal 2021.
- Inhibikase Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2021 was $60.39K, a 1140.06% increase from fiscal 2020.
- Inhibikase Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2020 was $4.87K.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2022-12-31 | $67.00K 10-K · filed 2023-03-31 | |
| 2022-03-31 | $67.00K 10-Q · filed 2023-11-14 | |
| 2021-12-31 | $60.39K 10-K · filed 2023-03-31 | |
| 2021-03-31 | $60.39K 10-Q · filed 2022-11-14 | |
| 2020-12-31 | $4.87K 10-K · filed 2022-03-31 | |
| 2020-03-31 | $4.87K 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |